ALMANAC

From Wikipedia, the free encyclopedia

This does not cite its references or sources.
Please help improve this article by introducing appropriate citations. (help, get involved!) This article has been tagged since June 2006.

ALMANAC is the name of a major breast cancer trial. It stands for "Axillary Lymphatic Mapping Against Nodal Axillary Clearance." This major randomised trial performed in several centres in the UK produced clear evidence that sentinel node biopsy (SNB), used to stage axillary spread of disease, can be used with low failed localisation and false negative rates, provided both radioisotope and blue dye are used to locate the sentinel nodes.

Compared to standard axillary management, SNB results in greatly decreased arm problems and increased quality of life, without any increase in cancer-related anxiety. There is no evidence of a difference in local recurrence rates, though longer-term evidence on this is awaited from other studies.


This medical article is a stub. You can help Wikipedia by expanding it.
Retrieved from "http://en.wikipedia.org../../../a/l/m/ALMANAC_4e8d.html"